SCHEMBL6209347

SCHEMBL6209347

Brc1cnc(Nc2cccc3cccnc23)nc1NCc1ccccn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 8/20 0.53
FGFR1 P11362 2/20 0.53
KDR P35968 2/20 0.53
PTK2 Q05397 2/20 0.52
PTK2B Q14289 2/20 0.52
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
BLM P54132 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
APAF1 O14727 2/20 0.42
POLB P06746 1/20 0.42
CDK1 P06493 2/20 0.41
CDK2 P24941 2/20 0.41
CCNB1 P14635 1/20 0.41
CCNE1 P24864 1/20 0.41
MAPT P10636 2/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6211993 0.89 IGF1R (0.48) IGF1RFGFR1KDRPTK2PTK2B
SCHEMBL6216021 0.85 PTK2 (0.50) IGF1RFGFR1KDRPTK2PTK2B
SCHEMBL6212168 0.84 PTK2 (0.52) IGF1RFGFR1KDRPTK2PTK2B
SCHEMBL6212242 0.83 ZAP70 (0.56) IGF1RFGFR1KDRPTK2PTK2B
SCHEMBL6212411 0.80 PTK2 (0.50) IGF1RFGFR1KDRPTK2PTK2B
SCHEMBL6210462 0.80 TDO2 (0.55) IGF1RFGFR1KDRPTK2PTK2B
SCHEMBL6214553 0.78 PTK2 (0.62) IGF1RFGFR1KDRPTK2PTK2B
SCHEMBL31020173 0.78 MEN1 (0.62) KDRMEN1KMT2ABLML3MBTL1
SCHEMBL6211059 0.74 GBA1 (0.50) IGF1RFGFR1KDRPTK2PTK2B
SCHEMBL4065848 0.74 CA2 (0.64) IGF1RFGFR1KDRPTK2PTK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 EP claimed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US claimed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 WO claimed
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 EP disclosed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US disclosed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220177-A1 Compound for the treatment of abnormal cell growth CCNA1, CCNB1, CCNT1 IGF1R 93/4885FGFR1 21/4885KDR 741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.